

REMARKS

Claims 2-20 are pending. Claims 2 and 12 and portions of the specification have been amended to insert the SEQ ID NO identifiers associated with the sequences listed in the accompanying Sequence Listing. Claim 12 was also amended to include an option at position Z which had been inadvertently left out.


Support for the inclusion of SEQ ID NO 43 and 44 and the amendments to claim 12 can be found throughout the specification and claims as originally filed, for example, at the paragraph bridging pages 8 and 9, the last paragraph on page 9, the paragraph ending at the top of page 15, and claim 1 as originally filed. Support for SEQ ID NO: 42 is in Fig. 2 and this sequence identifier was inadvertently omitted from the specification. Accordingly, no new matter is added by these amendments.

Applicants respectfully request entry of this amendment and believe that the present application is now in condition for allowance. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.

No fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: 15 July 2005


Karen R. Zachow
Registration No. 46,332

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: (858) 458-8513
Facsimile: (858) 552-1936